lutetium-lu-177-dotatate and Esthesioneuroblastoma--Olfactory

lutetium-lu-177-dotatate has been researched along with Esthesioneuroblastoma--Olfactory* in 1 studies

Other Studies

1 other study(ies) available for lutetium-lu-177-dotatate and Esthesioneuroblastoma--Olfactory

Article	Year
Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT. Clinical nuclear medicine, 2015, Volume: 40, Issue:4 A 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of 111In-octreotide over 8 months and 3 treatments of 177Lu-DOTATATE over 4 months, which helped alleviate his symptoms and improved his quality of life; however, the tumor ultimately progressed and he passed away shortly thereafter. PRRT with 111In-octreotide or 177Lu-DOTATATE could play a role in the management of esthesioneuroblastoma. Topics: Esthesioneuroblastoma, Olfactory; Humans; Male; Middle Aged; Nasal Cavity; Nose Neoplasms; Octreotide; Organometallic Compounds; Radiopharmaceuticals	2015

Article

Year

Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.

Clinical nuclear medicine, 2015, Volume: 40, Issue:4

A 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of 111In-octreotide over 8 months and 3 treatments of 177Lu-DOTATATE over 4 months, which helped alleviate his symptoms and improved his quality of life; however, the tumor ultimately progressed and he passed away shortly thereafter. PRRT with 111In-octreotide or 177Lu-DOTATATE could play a role in the management of esthesioneuroblastoma.

Topics: Esthesioneuroblastoma, Olfactory; Humans; Male; Middle Aged; Nasal Cavity; Nose Neoplasms; Octreotide; Organometallic Compounds; Radiopharmaceuticals

2015